<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">08732</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2021.08732</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Der besondere Fall</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Hämatologie</subject>
          <subject>Klinische Pharmakologie und Toxikologie</subject>
          <subject>Pathologie / Histologie</subject>
          <subject>Pneumologie</subject>
          <subject>Radiologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hypersensitivitäts-Pneumonitis</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Egli</surname>
            <given-names>Seraina</given-names>
          </name>
          <email>seraina.egli@ksw.ch</email>
          <aff>Brauerstrasse 15 | Winterthur | Switzerland | 8400 | SWITZERLAND | +41764954843</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Hess</surname>
            <given-names>Thomas</given-names>
          </name>
          <email/>
          <aff>Kantonsspital Winterthur, Klinik für Pneumologie</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Goede</surname>
            <given-names>Jeroen</given-names>
          </name>
          <email/>
          <aff>Kantonsspital Winterthur,
Klinik für Medizinische Onkologie und Hämatologie</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="will-be" iso-8601-date="2021.10.27">
        <day>27</day>
        <month>10</month>
        <year>2021</year>
      </pub-date>
      <volume>21</volume>
      <issue>4344</issue>
      <fpage>758</fpage>
      <lpage>760</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>A 70 years old man presented with asthenia, dyspnea and dry cough since a few days. His medical history included primary myelofibrosis (MF) diagnosed 1.5 month earlier, treated with HU since 1 month. The patient had stopped the HU-treatment 4 days before because he suspected a causative association with the HU-therapy.

CT-scan ruled out pulmonary embolism but showed apical predominant patchy ground-glass opacities. Elevated inflammatory markers were found in the serum (CRP 155 mg/l). Bacterial pneumonia was suspected and antibiotic treatment with Co-Amoxicillin and Clarithromycin was started with prompt remission. On discharge, the therapy with HU was resumed.

2 days later the Patient returned with aggravation of the symptoms. Chest X-ray showed pronounced infiltration of the upper lobes with small bilateral pleural effusions. Neither in the blood culture nor in the bronchoalveolar lavage (BAL) an infectious cause was found. BAL showed a picture compatible with hypersensitivity pneumonitis. HU was stopped immediately and treatment with prednisolone 40 mg was initiated. With this therapy the symptoms regressed quickly. 

Only a few cases (&lt; 20) of HU induced pneumonitis have been described in the literature.

The signs and symptoms of HU induced pneumonitis are initially mostly misinterpreted as a bacterial pneumonia. 

Most important is the immediate cessation of the HU-therapy. There exists no recommendation regarding corticosteroid treatment.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
